Skip to main content
Indietro

Protein Misfolding and Degenerative Diseases: Mechanisms, Consequences, and Therapeutic Approaches

Guida di studio - Note intelligenti

Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.

Protein Folding and Quality Control

General Facts on Protein Folding

Protein folding is a critical cellular process where newly synthesized polypeptides acquire their functional three-dimensional structure. Proper folding is essential for protein function, and errors can lead to disease.

  • Amino acid sequence determines the final structure of a protein.

  • Cellular environment (temperature, pH) influences folding efficiency.

  • Protein Quality Control (PQC) system ensures correct folding and removes damaged proteins.

Example: Chaperone proteins assist in folding and prevent aggregation.

The Protein Quality Control (PQC) System

The PQC system acts as the cell's maintenance and repair department, ensuring proteins are correctly folded and removing those that are damaged or misfolded.

  • Folding Chaperones: Help newly made proteins fold into their correct shape.

  • Holding Chaperones: Hold unstable or unfolded proteins to prevent clumping.

  • Unfolding Chaperones: Attempt to refold or unfold misfolded proteins for another folding attempt.

  • Proteases: Degrade proteins that cannot be repaired, recycling them into peptides.

If misfolded proteins accumulate, they can form soluble oligomers, insoluble aggregates, or amyloid fibrils.

Mechanisms and Causes of Protein Misfolding

Post-Translational Modifications (PTMs)

PTMs are chemical modifications that proteins undergo after synthesis. They can stabilize correct folding, but errors in PTMs may drive misfolding and disease.

  • Phosphorylation: Addition of phosphate groups using ATP.

  • Acetylation: Addition of acetyl groups from Acetyl-CoA to lysine residues.

  • Glycosylation: Addition of carbohydrate (sugar) groups.

  • Lipidation: Addition of lipid groups to cysteine residues.

  • Hydrolysis: Breakage of peptide bonds by water.

Example: Hyperphosphorylation of tau protein leads to aggregation in Alzheimer's disease.

Causes of Misfolding and Protein Aggregation

Protein aggregation occurs when misfolded proteins accumulate and the PQC system is overwhelmed.

  • Changes in cellular conditions (e.g., stress, mutations) increase misfolded proteins.

  • Aggregation is favored when hydrophobic amino acid residues, β-sheet predisposition, and low net charge are present.

  • Chaperones assist folding and stabilize intermediates; if unsuccessful, proteins may form aggregates or be degraded.

Protein aggregation is a 2-stage event:

  1. Nucleation: Proteins attach reversibly to a growing nucleus.

  2. Growth: Proteins attach irreversibly, forming larger aggregates.

Cellular Consequences of Protein Aggregation

Pathogenic Mechanisms

Protein aggregation can lead to two main types of pathogenesis:

  • Loss-of-function: Premature degradation of misfolded proteins by PQC leads to protein deficiency diseases.

  • Gain-of-function: Accumulation of misfolded proteins causes toxicity and disease pathology.

Some diseases display both mechanisms.

  • Cellular consequences include stress response, proteasome inhibition, chaperone sequestration, oxidative stress, mitochondrial dysfunction, and cell death.

Protein-Misfolding Diseases

Types and Examples

Protein-misfolding diseases occur when proteins fail to fold correctly, are unstable, are not trafficked properly, or form toxic aggregates.

  • Fails to fold correctly: Cystic fibrosis, Marfan syndrome, amyotrophic lateral sclerosis.

  • Not stable enough: Many forms of cancer.

  • Fails to be correctly trafficked: Familial hypercholesterolemia, α1-antitrypsin deficiency.

  • Forms insoluble aggregates: Neurodegenerative diseases (Alzheimer’s, type II diabetes, Parkinson’s).

Classification of Conditions

  • Familial: Genetically inherited, symptoms appear during childhood (e.g., Huntington's disease).

  • Sporadic: Late onset, not associated with gene mutations (e.g., most Alzheimer's and Parkinson's cases).

  • Transmissible: Spread through infectious proteins (e.g., prion diseases).

Table: Clinical, Pathological, and Biochemical Features of Neurodegenerative Diseases

Disease

Mode of Transmission

Clinical Features

Affected Regions of the Brain

Protein Involved

Cellular Location of Aggregates

Alzheimer's

Sporadic (95%) or inherited (5%)

Progressive dementia

Hippocampus, cortex

Amyloid β and tau

Extracellular, cytoplasmic

Parkinson's

Mostly sporadic

Movement disorder

Substantia nigra, hypothalamus

α-Synuclein

Cytoplasmic

Huntington's

Inherited

Dementia, motor and psychiatric problems

Cortex, striatum

Huntingtin

Nuclear

Amyotrophic lateral sclerosis

Inherited/sporadic

Dementia, motor neuron degeneration

Motor cortex

Superoxide dismutase

Cytoplasmic

Transmissible spongiform encephalopathies

Sporadic (90%) or inherited (10%)

Dementia, ataxia

Various regions depending on disease

Prion protein

Extracellular

Amyloidoses and Amyloid Fibril Formation

Amyloidoses

Amyloidoses are disorders of protein misfolding, highly relevant due to their association with neurodegenerative diseases and type II diabetes.

  • Systemic amyloidoses: Fibrils accumulate throughout the body.

  • Organ-limited amyloidoses: Fibrils accumulate in a specific organ (e.g., brain).

Abnormal folding leads to insoluble aggregates deposited as amyloid fibrils in extracellular tissues.

Amyloid Fibril Formation

The formation of amyloid fibrils occurs in three steps:

  1. Alignment of molecules to form β-sheets: Fastest stage, involves hydrogen bonds.

  2. Formation of cross-β structure: Slower, involves Van-der-Waals forces and interdigitation of side chains ("steric zipper").

  3. Fibril formation: Involves non-covalent bonds.

Toxicity: Amyloid fibrils can form spherical, chain-like, or annular pore-like structures that disrupt cell membranes.

Neurodegenerative Diseases

Alzheimer's Disease

Alzheimer's is the most common progressive neurodegenerative disorder, characterized by massive loss of neurons.

  • Accumulation of amyloid β-protein (extracellular) and tau protein (intracellular).

  • Formation of amyloid plaques (Aβ) and neurofibrillar tangles (NFTs).

  • Symptoms: Memory impairment, inability to think independently, loss of function.

Parkinson's Disease

Parkinson's disease involves the aggregation of α-synuclein into Lewy bodies, leading to movement disorders.

  • Symptoms: Muscular rigidity, postural instability, resting tremor.

  • Dopamine levels are reduced in affected neurons, impairing normal movement.

Huntington's Disease

Huntington's is a polyglutamine disease caused by gene mutation, resulting in extra glutamine residues in the protein sequence.

  • Accumulation of misfolded Huntingtin protein.

  • Formation of toxic inclusions in brain cells.

  • Degeneration of glutamatergic striatal neurons.

Transmissible Spongiform Encephalopathies (TSEs)

TSEs are caused by abnormal folding of prion proteins.

  • Normal prion protein (PrPc): Membrane glycoprotein, water-soluble, proteinase-sensitive.

  • Abnormal prion (PrPSc or PrPTSE): Resistant to proteases, precipitates as insoluble amyloid.

Therapeutic Solutions

Main Approaches

Therapeutic strategies aim to prevent or reverse protein aggregation and its toxic effects.

  1. Inhibition of protein aggregation

  2. Interference with post-translational peptide changes before misfolding/aggregation

  3. Upregulation of molecular chaperones or aggregate-clearance mechanisms

Examples of Therapeutic Solutions

  • Laminin: Inhibits amyloid β (Aβ) fibril neurotoxicity.

  • β- and γ-secretase inhibitors: Prevent formation of amyloid plaques.

  • Inhibition of tau protein phosphorylation: Prevents tau aggregation.

  • Clonidine and Minoxidil: Enhance clearance of aggregate proteins, including mutant Huntingtin and α-synuclein.

Curing Alzheimer's Disease

Alzheimer's disease affects millions worldwide, with drug research focused on preventing Aβ formation and blocking amyloid plaque formation.

  • Current drugs target Aβ aggregation, tau protein, and mitochondrial stabilization.

Drug

Mechanism of Action

Stage of Development

Tramiprosate

Direct Aβ binding to prevent aggregation

Completed Phase III/discontinued

ACC-001

Active Aβ vaccination

Phase II (safety, proof of concept)

Bapineuzumab

Anti-Aβ monoclonal antibodies

Phase III (efficacy in AD)

PF-04494700

RAGE inhibitor

Phase II (safety, proof of concept)

Semagacestat

γ-secretase inhibitor

Phase III (efficacy in AD)

Rember

Tau aggregation inhibitor

Entering Phase II (efficacy in AD)

NAP (AL-108)

Microtubule stabilizer

Phase II (safety, cognitive enhancement)

Dimebon

Mitochondrial stabilizer

Phase III (efficacy in AD)

Additional info: Protein misfolding and aggregation are central to the pathology of many degenerative diseases, especially those affecting the nervous system. Understanding the molecular mechanisms and cellular consequences is essential for developing effective therapies.

Pearson Logo

Study Prep